Research and Markets (http://www.researchandmarkets.com/research/n5wcmx/chronic) has announced the addition of the "Chronic Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.

The Report, Chronic Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

Key Topics Covered:

  • A snapshot of the global Market and Phase III therapeutics scenario for Chronic Pain.
  • A review of the marketed products under prescription for Chronic Pain, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for Chronic Pain with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for Chronic Pain drugs in the United States, Europe and Asian Regions with location details.

Benefits of this Report:

  • Evaluate the marketing status and exclusivity details of Chronic Pain key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for Chronic Pain.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Chronic Pain.
  • API intelligence over marketed drugs for Chronic Pain and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline drugs.

Report Structure:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Chronic Pain

7. Phase III Drugs for Chronic Pain

8. Discontinued Drugs for Chronic Pain

9. Appendix

10. Methodology

11. Consulting Services

12. Contact Us

13. Disclaimer

For more information visit http://www.researchandmarkets.com/research/n5wcmx/chronic